Clinical trials: CtDNA
Paraneoplastic Neurological Syndromes
Liquid Biopsy in Paraneoplastic Neurological Syndromes
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined…
- Trial name
- LiB-PNS (NCT07491328)
- Testing
- CTC & ctDNA analysis
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Metastatic Colon Cancer
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
Background : In unresectable mCRC, a de-escalation strategy using maintenance or chemotherapy (CT) discontinuation in selected cases is considered as a valid option in non-progressive patients after a first-line induction of…
- Trial name
- DIAMOND (NCT06446557)
- Testing
- treatment adaptation guided by ctDNA variation, standard management
- Where
- France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Rouen
Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in…
- Conditions
- Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer
- Trial name
- NCT07062016
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic…
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood
- Trial name
- STRATUS (NCT06717243)
- Testing
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Where
- 2 sites in United States, Greece
- Volunteers
- 111 people
- Sponsor
- Oncology Center of Biochemical Education And Research
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Lung Cancer, Stage III Lung Cancer
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
Multi-center observational clinical study to evaluate the application value of ctDNA monitoring in efficacy assessment and relapse prediction in patients diagnosed with unresectable, locally advanced NSCLC receiving CRT with or…
- Conditions
- Lung Cancer, Stage III Lung Cancer, Unresectable Lung Carcinoma
- Trial name
- NCT05641870
- Testing
- Sample collection, Characterization of the tumoral tissue genomic alterations, Chemoradiation treatment regimen and maintenance (if amenable)
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Parc de Salut Mar
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Rectal Cancer, Non Metastatic Rectal Cancer
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy.
- Trial name
- NCT05629442
- Testing
- ctDNA
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Diffuse Large B Cell Lymphoma
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA…
- Trial name
- RT-CAR (NCT05675982)
- Testing
- CAR-T cells monitoring
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Henri Becquerel
NSCLC
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis, vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to dynamically monitor ctDNA in cerebrospinal fluid (CSF)…
- Trial name
- NCT06315686
- Testing
- pemetrexed
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Colorectal Cancer
Influence of the Surgical Technique Used for Colectomies on the Concentration of Circulating Tumor DNA and the Presence of Circulating Tumor Cells: Comparison of the "no Touch" Technic With Either First Clamping of the Mesenteric Vessels or First Mobilization of the Tumor Followed by Clamping.
Colectomy is the most commonly used therapeutic approach for the treatment of non-metastatic colorectal cancer. This approach is generally very effective however the rate of recurrence and the appearance of metachronous…
- Trial name
- ADNCHIR (NCT03809403)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B Cell Lymphoma (DLBCL)
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
- Trial name
- GRAIL (NCT06050694)
- Testing
- glofitamab
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Neoadjuvant Chemotherapy
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the…
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Circulating Tumor DNA
- Trial name
- NCT03688035
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhiyong Yu
Lung Cancer
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
This study aims to promote the rational use of liquid biopsy in the clinical detection of lung cancer. Lung cancer is a malignant tumor with high morbidity and mortality worldwide.
- Trial name
- LUNGCA (NCT03317080)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
Ovarian Cancer
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.
Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance or salvage therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status as well as specific resistance mechanism are…
- Trial name
- NCT05458973
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Non Small Cell Lung Cancer
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.
- Trial name
- LIBERTI (NCT03553550)
- Testing
- biospecimen collection
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Addario Lung Cancer Medical Institute
Biliary Tract Cancer
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea.
- Trial name
- NCT07151118
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Triple Negative Breast Cancer
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) surveillance component and a therapeutic component.
- Trial name
- c-TRAK-TN (NCT03145961)
- Testing
- Pembrolizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 208 people
- Sponsor
- Institute of Cancer Research, United Kingdom